Email this article Contrast induced nephropathy after transcatheter aortic valve implantation
- Authors: Kranin D.L.1, Stets V.V.1, Pestovskaya O.R.1, Dunaev E.P.1, Nazarov D.A.1, Gaydukov A.V.1, Mashtanov G.V.1, Zamskiy K.S.1, Fedorov A.Y.1, Varochkin K.A.1, Kurnosov S.A.1
-
Affiliations:
- Burdenko Main Military Clinical Hospital
- Issue: Vol 45, No 3 (2017)
- Pages: 242-246
- Section: ARTICLES
- URL: https://almclinmed.ru/jour/article/view/545
- DOI: https://doi.org/10.18786/2072-0505-2017-45-3-242-246
- ID: 545
Cite item
Full Text
Abstract
Background: Aortic stenosis ranks the third in the structure of all cardiovascular diseases, conceding only to arterial hypertension and coronary heart disease. Transcatheter aortic valve implantation (TAVI) is a promising area of interventional endovascular surgery that enables to provide surgical care to a significant group of the patients with severe aortal stenosis.
Aim: To assess the efficacy of prevention of the contrast induced nephropathy (CIN) in patients who underwent TAVI under general anesthesia.
Materials and methods: We evaluated incidence of CIN in 19 patients who underwent surgery for aortic valve stenosis under general anesthesia with hemodilution and intravenous magnesium sulfate 1 g before administration of the contrast.
Results: Laboratory signs of nephropathy within the first 72 hours after the intervention were found in 8/19 (42.1%) of patients. In 4 (50%) of patients with CIN, its risk had been very high, in 3 (38%), high, and in 1 (12%), moderate. The results obtained are compatible with the contrast-induced acute kidney injury risk estimated from the Mehran-Barrett-Parfrey scale.
Conclusion: The used technique of hemodilution and magnesium-based prevention can be considered a safe method of CIN prophylaxis in TAVI patients.
About the authors
D. L. Kranin
Burdenko Main Military Clinical Hospital
Email: fake@neicon.ru
MD, PhD, Head of Center of Cardiovascular Surgery
3 Gospital'naya ploshchad', Moscow, 105229, Russian Federation
РоссияV. V. Stets
Burdenko Main Military Clinical Hospital
Email: fake@neicon.ru
MD, Head of Center of Anesthesiology and Intensive Care
3 Gospital'naya ploshchad', Moscow, 105229, Russian Federation
РоссияO. R. Pestovskaya
Burdenko Main Military Clinical Hospital
Email: fake@neicon.ru
MD, PhD, Head of Center of Functional Diagnostics
3 Gospital'naya ploshchad', Moscow, 105229, Russian Federation
РоссияE. P. Dunaev
Burdenko Main Military Clinical Hospital
Author for correspondence.
Email: drdunaevep@yandex.ru
MD, Anesthesiologist, Сardiosurgical Intensive Care Unit, Center of Cardiovascular Surgery
3 Gospital'naya ploshchad', Moscow, 105229, Russian Federation. Tel.: +7 (499) 263 53 44
РоссияD. A. Nazarov
Burdenko Main Military Clinical Hospital
Email: fake@neicon.ru
MD, PhD, Senior Registrar, Department of Сardiac Surgery, Center of Cardiovascular Surgery
3 Gospital'naya ploshchad', Moscow, 105229, Russian Federation
РоссияA. V. Gaydukov
Burdenko Main Military Clinical Hospital
Email: fake@neicon.ru
MD, PhD, Head of Interventional and Diagnostic Radiology Department, Center of Cardiovascular Surgery
3 Gospital'naya ploshchad', Moscow, 105229, Russian Federation
РоссияG. V. Mashtanov
Burdenko Main Military Clinical Hospital
Email: fake@neicon.ru
MD, Head of Сardiosurgical Intensive Care Unit, Center of Cardiovascular Surgery
3 Gospital'naya ploshchad', Moscow, 105229, Russian Federation
РоссияK. S. Zamskiy
Burdenko Main Military Clinical Hospital
Email: fake@neicon.ru
MD, PhD, Department of Vascular Surgery, Center of Cardiovascular Surgery
3 Gospital'naya ploshchad', Moscow, 105229, Russian Federation
РоссияA. Yu. Fedorov
Burdenko Main Military Clinical Hospital
Email: fake@neicon.ru
MD, PhD, Head of Operation Department, Center of Cardiovascular Surgery
3 Gospital'naya ploshchad', Moscow, 105229, Russian Federation
РоссияK. A. Varochkin
Burdenko Main Military Clinical Hospital
Email: fake@neicon.ru
MD, Registrar, Department of Сardiac Surgery, Center of Cardiovascular Surgery
3 Gospital'naya ploshchad', Moscow, 105229, Russian Federation
РоссияS. A. Kurnosov
Burdenko Main Military Clinical Hospital
Email: fake@neicon.ru
MD, Registrar, Department of Сardiac Surgery, Center of Cardiovascular Surgery
3 Gospital'naya ploshchad', Moscow, 105229, Russian Federation
РоссияReferences
- Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24(13): 1231–43. doi: https://doi.org/10.1016/S0195-668X(03)00201-X.
- Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540): 1005–11. doi: 10.1016/S0140-6736(06)69208-8.
- Faggiano P, Antonini-Canterin F, Erlicher A, Romeo C, Cervesato E, Pavan D, Piazza R, Huang G, Nicolosi GL. Progression of aortic valve sclerosis to aortic stenosis. Am J Cardiol. 2003;91(1): 99–101. doi: https://doi.org/10.1016/S0002-9149(02)03011-4.
- Davies H. Catheter-mounted valve for temporary relief of aortic insufficiency. Lancet. 1965;285(7379): 250. doi: https://doi.org/10.1016/S0140-6736(65)91529-1.
- Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106(24): 3006–8. doi: https://doi.org/10.1161/01.CIR.0000047200.36165.B8.
- McCullough PA. Renal complications of contrast media: Contrast-induced nephropathy. In: King SB, Yeung AC, editors. Interventional cardiology. New York: McGraw-Hill Medical; 2007. p. 239–49.
- Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J. 2012;33(19): 2403–18. doi: 10.1093/eurheartj/ehs255.
- Konigstein M, Ben-Assa E, Abramowitz Y, Steinvil A, Leshem Rubinow E, Havakuk O, Arbel Y, Halkin A, Keren G, Banai S, Finkelstein A. Usefulness of updated valve academic research consortium- 2 criteria for acute kidney injury following transcatheter aortic valve implantation. Am J Cardiol. 2013;112(11): 1807–11. doi: 10.1016/j.amjcard.2013.07.048.
- Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, Ree M, Shah AI, Burchette RJ. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium- induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008;300(9): 1038–46. doi: 10.1001/jama.300.9.1038.
- Scherner M, Wahlers T. Acute kidney injury after transcatheter aortic valve implantation. J Thorac Dis. 2015;7(9): 1527–35. doi: 10.3978/j.issn.2072-1439.2015.06.14.
- Firouzi A, Maadani M, Kiani R, Shakerian F, Sanati HR, Zahedmehr A, Nabavi S, Heidarali M. Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention. Int Urol Nephrol. 2015;47(3): 521–5. doi: 10.1007/s11255-014-0890-z.
- Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S112–9. doi: http://dx.doi.org/10.1053/ajkd.1998.v32.pm9820470.
- Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7): 1393–9. doi: 10.1016/j.jacc.2004.06.068.
- Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354(4): 379–86. doi: 10.1056/NEJMcp050801.
Supplementary files
